[
    [
        {
            "time": "2018-10-16",
            "original_text": "AstraZeneca's Breast Cancer Candidate BLA Gets Priority Review",
            "features": {
                "keywords": [
                    "AstraZeneca",
                    "Breast Cancer",
                    "BLA",
                    "Priority Review"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "AstraZeneca's Breast Cancer Candidate BLA Gets Priority Review",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-10-17",
            "original_text": "Pharma Stock Roundup: JNJ's Q3 Earnings, RHHBY's Sales, FDA Nod to Lilly's Reyvow",
            "features": {
                "keywords": [
                    "Pharma",
                    "Stock",
                    "JNJ",
                    "Q3 Earnings",
                    "RHHBY",
                    "Sales",
                    "FDA",
                    "Lilly",
                    "Reyvow"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Pharma Stock Roundup: JNJ's Q3 Earnings, RHHBY's Sales, FDA Nod to Lilly's Reyvow",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-11-19",
            "original_text": "AbbVie Receives CHMP Positive Opinion for Upadacitinib (RINVOQ™) for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis",
            "features": {
                "keywords": [
                    "AbbVie",
                    "CHMP",
                    "Positive Opinion",
                    "Upadacitinib",
                    "RINVOQ™",
                    "Rheumatoid Arthritis"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "AbbVie Receives CHMP Positive Opinion for Upadacitinib (RINVOQ™) for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        }
    ]
]